Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease

Clinical Infectious Diseases

Volumn 47, Issue 9, 2008, Pages 1209-1215

  Sullivan, Ryan J ^a   Pantanowitz, Liron ^b   Casper, Corey ^c,d   Stebbing, Justin ^e   Dezube, Bruce J ^a,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ALTIZUMAB; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CD 20; CIDOFOVIR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FOSCARNET; GANCICLOVIR; IMATINIB; INCYCLINIDE; INTERLEUKIN 6 ANTIBODY; PACLITAXEL; PREDNISONE; RAPAMYCIN; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL THERAPY; CARCINOGENESIS; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HERPES VIRUS INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UPREGULATION; VIROLOGY; VIRUS REPLICATION; HUMAN HERPESVIRUS 8; PATHOGENICITY;

GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, PRIMARY EFFUSION; SARCOMA, KAPOSI;

EID: 53349095351     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592298     Document Type: Review

References (67)

1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-9.
2. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-91.
3. Soulier J, Grollet L, Oskenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86:1276-80.
4. Grossman WJ, Radhi M, Schauer D, et al. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. Blood 2005; 106:1203-6.
5. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94:1204-10.
6. Chatlynne LG, Ablashi DV. Seroepidemiology of Kaposi's sarcoma -associated herpesvirus (KSHV). Semin Cancer Biol 1999; 9:175-85.
7. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 2003; 17:1717-30.
8. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syphilol 1872; 4:265.
9. Taylor JF, Templeton AC, Vogel CL, Ziegler JL, Kyalwazi SK. Kaposi's sarcoma in Uganda: a clinico-pathological study. Int J Cancer 1971; 8:122-35.
10. Stribling J, Weitzner S, Smith GV. Kaposi's sarcoma in renal allograft recipients. Cancer 1978; 42:442-6.
11. Hymes KB, Cheung T, Greene JB, et al. Kaposi's sarcoma in homosexual men - a report of eight cases. Lancet 1981; 2:598-600.
12. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 2000; 335:123-8.
13. Grossman Z, Iscovich J, Schwartz F, et al. Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8. Mayo Clin Proc 2002; 77:905-9.
14. Casper C, Krantz E, Selke S, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis 2007; 195:30-6.
15. Casper C, Redman M, Huang ML, et al. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr 2004; 35:233-8.
16. Taylor MM, Chohan B, Lavreys L, et al. Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis 2004; 190:484-8.
17. Plancoulaine S, Abel L, van Beveren M, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet 2000; 356:1062-5.
18. Casper C, Carrell D, Miller KG, et al. HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sex Transm Infect 2006; 82:229-35.
19. Casper C, Wald A, Pauk J, et al. Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men. J Infect Dis 2002; 185:990-3.
20. Cannon MJ, Dollard SC, Smith DK, et al. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med 2001; 344:637-43.
21. Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006; 355:1331-8.
22. Luppi M, Barozzi P, Santagostino G, et al. Molecular evidence of organ-related transmission of kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 2000; 96:3279-81.
23. Barozzi P, Luppi M, Facchetti F, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9:554-61.
24. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials 2001; 2:493-554.
25. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 2006; 1:273-96.
26. Cotter MA 2nd, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology 1999; 264:254-64.
27. Friborg J Jr, Kong W, Hottinger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402:889-94.
28. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6:1121-7.
29. Sullivan R, Dezube BJ, Koon HB. Signal transduction targets in Kaposi's sarcoma. Curr Opin Oncol 2006; 18:456-62.
30. Sodhi A, Montaner S, Gutkind JS. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis? FASEB J 2004; 18:422-7.
31. Field N, Low W, Daniels M, et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 2003; 116:3721-8.
32. Sun Q, Zachariah S, Chaudhary PM. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-κB activation. J Biol Chem 2003; 278:52437-45.
33. Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric Castleman's disease. Am J Hematol 2008; 83:498-503.
34. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106:2627-32.
35. Nagy S, Gyulai R, Kemeny L, Szenohradszky P, Dobozy A. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000; 69:2230-1.
36. Paparizos VA, Kyriakis KP, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr 2002;30:257-8.
37. Strickler HD, Goedert JJ, Bethke FR, et al. Human herpesvirus 8 cellular immune responses in homosexual men. J Infect Dis 1999; 180:1682-5.
38. Guihot A, Dupin N, Marcelin AG, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194:1078-88.
39. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002; 76:2634-40.
40. Krown SE, Lee JY, Dittmer DP; AIDS Malignancy Consortium. More on HIV-associated Kaposi's sarcoma. N Engl J Med 2008; 358:535-6.
41. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371:674-80.
42. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335:606-11.
43. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood 2004; 104:810-4.
44. Hyun TS, Subramanian C, Cotter MA 2nd, et al. Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. J Virol 2001; 75:8761-71.
45. Caselli E, Galvan M, Cassai E, et al. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood 2005; 106:2790-7.
46. DiLorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol 2007; 8:167-76.
47. Casper C, Wald A. The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. Curr Top Microbiol Immunol 2007; 312:289-307.
48. Little RF, Merced-Galindez F, Staskus K, et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis 2003; 187:149-53.
49. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 2004; 113:124-36.
50. Stallone G, Schena A, Infante B, et al., Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-23.
51. Braza JM, Sullivan RJ, Bhargava P, Pantanowitz L, Dezube BJ. Images in HIV/AIDS: pericardial primary effusion lymphoma. AIDS Read 2007; 17:250-2.
52. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88:645-56.
53. Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004; 28:1401-16.
54. Oksenhendler E, Clauvel JP, Jouveshomme S, et al. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol 1998; 57:266.
55. Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21:3948-54.
56. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96:2537-42.
57. An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004; 18:1699-704.
58. Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109:2165-73.
59. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129:3-17.
60. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 2002; 35:880-2.
61. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25:3350-6.
62. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147:836-9.
63. Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood 2007; 110:4132-3.
64. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005;23:5224-8.
65. Casper C, Krantz EM, Kuntz SR, et al. Valganciclovir for suppression of human herpesvirus 8 (HHV-8) replication: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2008; 198:23-30.
66. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632-4.
67. Valencia ME, Moreno V, Martinez P, Casado I. Favorable outcome of Castleman's disease treated with oral valganciclovir [in Spanish]. Med Clin (Barc) 2005; 125:399.